Biotech Startups

Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection. Its oral therapies target gut dysbiosis-driven conditions.

5 investors

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.

5 investors

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men. The therapy is being evaluated in Phase 2 and Phase 3 clinical trials.

5 investors

Vertero develops therapies for neurodegenerative diseases by targeting causative mechanisms in the peripheral nervous system rather than addressing symptoms alone. The company uses discoveries in microbiology, pharmacology, and neuroscience to create novel drug treatments for patients with unmet needs.

5 investors

Vibe Bio funds and supports overlooked drug development programs by combining AI and capital to identify promising treatments and reduce funding gaps. The company serves biotech developers working on life-changing cures that lack traditional funding pathways.

5 investors

VIDA provides imaging data collection and AI-powered analysis services to life sciences companies for accelerating drug development and clinical trials. The company serves therapeutic researchers and clinical development teams in the biotech and pharmaceutical sectors.

5 investors

ViewMind develops technology that provides objective, measurable data about brain function under cognitive stress to support clinical evaluation. The company's solution complements traditional biomarkers and imaging for healthcare providers.

5 investors

ViewsML applies AI to support the development and delivery of precision medicines, including virtual IHC technology for pathology. It operates in the AI-driven healthcare and diagnostics space.

5 investors

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

5 investors

Vitara Biomedical develops medical technology for the care of extremely premature newborns. The company is rooted in neonatology research from Children's Hospital of Philadelphia.

5 investors

Develops a thermostable, single-injection vaccine formulation platform.

5 investors

Vivalyx develops organ revitalization technology aimed at improving organ vitality for transplantation. The company works in the medical biotechnology field.

5 investors

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.

5 investors

Vivifi Medical develops a minimally invasive device to treat the underlying causes of Benign Prostatic Hyperplasia (BPH) in patients. The company builds urological medical devices and operates with a bi-coastal presence in Houston (Texas Medical Center) and Portland, Oregon.

5 investors

Vivodyne is a bio-AI company that develops lab-grown human tissues and robotic systems to generate causal biological data for therapeutic development. The platform produces high-resolution phenomic, transcriptomic, and proteomic data from human tissue models to enable drug discovery and development.

5 investors

Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies. Its team spans drug discovery, clinical development, and business strategy to bring new oncology treatments to patients.

5 investors

Watershed is a bioinformatics platform for data-driven discovery and collaboration, handling biological data from sequencing to mass spectrometry. It is used by researchers to analyze and manage biological data.

5 investors

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.

5 investors

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia. It is a publicly traded company listed on Nasdaq.

5 investors

Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.

5 investors

Xylo develops mechanism-based drug therapies targeting psychiatric and neurological disorders using computational and rational drug design approaches. The company serves patients and healthcare systems seeking novel treatments for complex neuropsychiatric conditions.

5 investors

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.

5 investors

YourChoice Therapeutics develops non-hormonal contraceptives for both women and men, aiming to provide birth control options without the risks associated with hormone-based methods. Its initial focus is an on-demand, low-cost non-hormonal female contraceptive, followed by a non-surgical, non-hormonal male contraceptive.

5 investors

Zylö Therapeutics develops therapeutic delivery technology, focusing on product development in the biotech and drug-delivery space.

5 investors